Analysts Chase Cheniere Higher as Street Targets Lag the Tape
Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish
LNG has added 10.6% in the past week to close at $330.32, a move that dwarfs the median gain of roughly 1.5% among its closest peers. CQP edged up less than 1% on the week. COP and CVX gained around 2%. The stock is now up more than 50% year to date, and Wednesday's print arrives with the share price above every major analyst target on the Street.
That gap between price and targets is the defining tension right now. Morgan Stanley raised its target to $322 on October 30, the same day Wells Fargo moved to $374 and Barclays lifted to $328. All three maintained positive ratings. The direction is unanimously upward: every change in the past month has been a raise, with no downgrades or neutral initiations. Yet the consensus target picture is fractured. Wells Fargo's $374 is the most bullish view on the Street and sits 13% above Friday's close. Morgan Stanley's $322 is already 2.5% below it. Barclays at $328 is barely above the tape. The bull case rests on Cheniere's fee-based contract structure, a 46-47 MT long-term book that generates highly visible cash flows, and a 2026 EBITDA guidance range of $7.9 billion to $8.4 billion that management already raised by $650 million in the second quarter. Bears point to re-contracting risk after 2037, assumed renewal rates running roughly 10% below current levels, and the possibility that weaker European spot prices or a US-China trade détente could compress the uncontracted portion of CMI sales.
Options positioning has eased materially since the pre-October 29 print, which itself delivered an 11% single-day gain. The put/call ratio has pulled back from the 0.61 spike recorded on October 23 to 0.539 now, just 0.76 standard deviations above its 20-day mean of 0.516. That is a notably calmer posture than investors carried into the last earnings release. The borrow market tells a similar story: shares available to lend relative to short interest are essentially unconstrained, with availability at the ceiling of what the system measures. Cost to borrow has fallen 31% over the past week to 0.28%, the lowest level in more than a month. Short interest, at 2.2% of the float, has drifted modestly lower over the past week and generates no meaningful signal on its own.
One institutional flow worth noting: FMR (Fidelity) added more than 2.1 million shares in the quarter ending September 30, a larger move in absolute terms than any other top-ten holder. That positions Fidelity as the fifth-largest disclosed holder with a 2.2% stake. Tortoise Capital, a specialist energy manager, added 383,000 shares in the same period to bring its stake to 1.4%. ORTEX puts the probability of Cheniere joining the S&P 500 at the December 2026 Quarterly Review at 40%, with the stock already 65.5% above the price threshold that would decide eligibility at $109.91. An S&P 500 addition would require index trackers to buy an estimated $14.2 billion of stock, equivalent to 24.4 days of normal trading volume, though past additions of a similar type have moved the expected way only 48% of the time.
Wednesday's print will test whether the company can sustain the guidance trajectory that drove the 11% post-earnings surge in late October, and whether management's expansion timeline for SPL Train 7 and CCL Stage 3 is tight enough to justify a price that has now run well beyond even the most optimistic targets set just days ago.
Stocks in this article
See the live data behind this article on ORTEX.
Open LNG on ORTEX →How this article was generated
- Generated
- 2 Nov 2026, 04:09
- Data as of
- 2 Nov 2026, 04:01
- Prompt version
- v1.0
- Data sources
- Short interestCost to borrowUtilizationOptions flowEarningsAnalyst consensusInstitutional positioningORTEX Alpha signalsRecent ORTEX notesAlt DataIndex RebalancePrevious Mi Articles
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.